Submission for OMB Review; 30-Day Comment Request; Early Career Reviewer Program Online Application and Vetting System (Center for Scientific Review), 20698-20699 [2020-07708]
Download as PDF
<![CDATA[
20698
Federal Register / Vol. 85, No. 72 / Tuesday, April 14, 2020 / Notices
jbell on DSKJLSW7X2PROD with NOTICES
Developers whose approved companion
diagnostics may be appropriate for
broader labeling are encouraged to
contact CDRH or CBER, as appropriate
to discuss. Developers of the companion
diagnostics discussed in the guidance as
an example should see the ‘‘Other Issues
for Consideration’’ section of this notice
for information regarding broader
labeling for those companion
diagnostics.
This guidance finalizes the draft
guidance entitled ‘‘Developing and
Labeling In Vitro Companion Diagnostic
Devices for a Specific Group or Class of
Oncology Therapeutic Products’’ dated
December 2018 (83 FR 63166).
Comments received on the draft
guidance were taken into consideration
when finalizing the guidance. Based on
the comments received, clarifications
were made and information regarding
the content of broader labeling was
added.
This guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The guidance represents the current
thinking of FDA on ‘‘Developing and
Labeling In Vitro Companion Diagnostic
Devices for a Specific Group of
Oncology Therapeutic Products.’’ It
does not establish any rights for any
person and is not binding on FDA or the
public. You can use an alternative
approach if it satisfies the requirements
of the applicable statutes and
regulations.
II. Other Issues for Consideration
Based on publicly available
information, which includes valid
scientific evidence (i.e., clinical and
scientific experience) with specific
companion diagnostics and the
associated therapeutic products, FDA
has concluded that certain statements
set forth in the FDA-approved labels of
these companion diagnostics, related to
intended use with therapeutic products,
can be modified. The specific
companion diagnostics are those
discussed as an example in the guidance
announced in this notice (i.e.,
companion diagnostics that identify
patients with NSCLC whose tumors
have EGFR exon 19 deletions or exon 21
(L858R) substitution mutations and are
suitable for treatment with a tyrosine
kinase inhibitor approved by FDA for
that indication). FDA believes it is
appropriate for sponsors to consider
modifying the intended use of these
companion diagnostics to describe the
specific group of oncology therapeutic
products, rather than listing individual
therapeutic product(s). The guidance
states that, rather than listing individual
therapeutic product(s), the intended use
VerDate Sep<11>2014
18:26 Apr 13, 2020
Jkt 250001
for the indication for the specific
companion diagnostics would be,
‘‘identifying patients with NSCLC
whose tumors have EGFR exon 19
deletions or exon 21 (L858R)
substitution mutations and are suitable
for treatment with a tyrosine kinase
inhibitor approved by FDA for that
indication.’’ It is possible for the
companion diagnostics to also have
other indications, not captured by the
broader indication. FDA encourages the
submission of PMA supplements,
identifying the change and referring to
this notice as the reason for the change,
to request modification of the intended
use of these companion diagnostics.
This broader labeling may enable greater
flexibility for clinicians in choosing the
most appropriate therapeutic product
based on a patient’s biomarker status.
In the Federal Register document that
announced the availability of the draft
guidance, FDA requested feedback on
specific issues, including challenges
with developing the evidence needed to
support broader companion diagnostic
labeling, challenges with submitting a
PMA supplement to broaden the
labeling of an approved companion
diagnostic and actions FDA can take to
facilitate or encourage broader
companion diagnostic labeling in
oncology. Comments that stakeholders
submitted to the docket for the draft
guidance are generally supportive of the
concept of broader labeling for
companion diagnostics in oncology to
facilitate the treatment of patients with
cancer. To encourage implementation of
broader labeling of companion
diagnostics in oncology, FDA is
finalizing the guidance and encouraging
submission of PMA supplements
containing the needed information for
FDA review of the modified labeling of
the companion diagnostics discussed in
the guidance as an example.
III. Paperwork Reduction Act of 1995
This guidance refers to previously
approved collections of information
found in FDA regulations and guidance.
These collections of information are
subject to review by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1995
(44 U.S.C. 3501–3521). The collections
of information in 21 CFR parts 801 and
809 have been approved under OMB
control number 0910–0485; the
collections of information in 21 CFR
part 807, subpart E, have been approved
under OMB control number 0910–0120;
the collections of information in 21 CFR
part 814, subparts A through E, have
been approved under OMB control
number 0910–0231; the collections of
information in 21 CFR part 814, subpart
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
H have been approved under OMB
control number 0910–0332; the
collections of information in the
guidance document ‘‘Requests for
Feedback and Meetings for Medical
Device Submissions: The Q-Submission
Program’’ have been approved under
OMB control number 0910–0756; and
the collections of information in the
guidance ‘‘De Novo Classification
Process (Evaluation of Automatic Class
III Designation)’’ have been approved
under OMB control number 0910–0844.
IV. Electronic Access
Persons with access to the internet
may obtain the guidance at either
https://www.fda.gov/medical-devices/
device-advice-comprehensiveregulatory-assistance/guidancedocuments-medical-devices-andradiation-emitting-products, https://
www.fda.gov/drugs/guidancecompliance-regulatory-information/
guidances-drugs, https://www.fda.gov/
vaccines-blood-biologics/guidancecompliance-regulatory-informationbiologics, or https://
www.regulations.gov.
Dated: April 8, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020–07816 Filed 4–13–20; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request; Early Career
Reviewer Program Online Application
and Vetting System (Center for
Scientific Review)
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
In compliance with the
Paperwork Reduction Act of 1995, the
National Institutes of Health (NIH) has
submitted to the Office of Management
and Budget (OMB) a request for review
and approval of the information
collection listed below.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 30-days of the date of this
publication.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
SUMMARY:
E:\FR\FM\14APN1.SGM
14APN1
20699
Federal Register / Vol. 85, No. 72 / Tuesday, April 14, 2020 / Notices
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact: Dr. Hope
Cummings, Project Clearance Liaison,
Center for Scientific Review, NIH, Room
4134, 6701 Rockledge Drive, Bethesda,
Maryland, 20892 or call non-toll-free
number (301) 402–4706 or Email your
request, including your address to:
hope.cummings@nih.gov. Formal
requests for additional plans and
instruments must be requested in
writing.
FOR FURTHER INFORMATION CONTACT:
This
proposed information collection was
previously published in the Federal
Register on January 31, 2020, pages
5677–5678 (85 FR 21) and allowed 60
days for public comment. No public
comments were received. The purpose
of this notice is to allow an additional
30 days for public comment. The Center
for Scientific Review (CSR), National
Institutes of Health, may not conduct or
sponsor, and the respondent is not
required to respond to, an information
collection that has been extended,
revised, or implemented on or after
October 1, 1995, unless it displays a
currently valid OMB control number.
SUPPLEMENTARY INFORMATION:
not had prior CSR review experience.
The goals of the program are to expose
these early career scientists to the peer
review experience so that they become
more competitive as applicants as well
as to enrich the existing pool of NIH
reviewers. Currently, the online
application software, the Early Career
Reviewer Application and Vetting
System, is accessed online by applicants
to the Early Career Reviewer Program
who provide information such as their
name, contact information, a description
of their areas of expertise, their study
section preferences, and their
professional Curriculum Vitae. This
Information Collection Request (ICR) is
to revise the Early Career Reviewer
Application and Vetting System to
include additional questions and be
more user friendly. Additional
questions are in line with NIH’s
renewed Interest in Diversity (NOT–
OD–20–031) and include questions such
as applicants’ race, ethnicity, gender,
disability, and disadvantage
backgrounds. Applicants can choose if
they would like to answer these
additional questions (i.e. optional).
Applicants are also now able to check
their eligibility before applying to the
program.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
505.
In compliance with Section
3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below.
Proposed Collection: Early Career
Reviewer Program Online Application
and Vetting System—0925–0695,
REVISION—expiration date 05/31/2020,
Center for Scientific Review (CSR),
National Institutes of Health (NIH).
Need and Use of Information
Collection: The Center for Scientific
Review (CSR) is the portal for NIH grant
applications and their review for
scientific merit. Our mission is to see
that all NIH grant applications receive
fair, independent, expert, and timely
reviews—free from inappropriate
influences—so NIH can fund the most
promising research. To accomplish this
goal, Scientific Review Officers (SRO)
form study sections consisting of
scientists who have the technical and
scientific expertise to evaluate the merit
of grant applications. Study section
members are generally scientists who
have established independent programs
of research as demonstrated by their
publications and their grant award
experiences.
The CSR Early Career Reviewer
program was developed to identify and
train qualified scientists who are early
in their scientific careers and who have
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Type of respondent
Average time
per response
(in hours)
Total annual
burden hour
Research scientists ..........................................................................................
1212
1
25/60
505
Total ..........................................................................................................
........................
1212
........................
505
Dated: March 30, 2020.
Hope M. Cummings,
Project Clearance Liaison, Center for
Scientific Review (CSR), National Institutes
of Health.
DEPARTMENT OF HOMELAND
SECURITY
[FR Doc. 2020–07708 Filed 4–13–20; 8:45 am]
[Internal Agency Docket No. FEMA–4485–
DR; Docket ID FEMA–2020–0001]
BILLING CODE 4140–01–P
Federal Emergency Management
Agency
Texas; Major Disaster and Related
Determinations
Federal Emergency
Management Agency, DHS.
ACTION: Notice.
AGENCY:
jbell on DSKJLSW7X2PROD with NOTICES
Number of
responses per
respondent
This is a notice of the
Presidential declaration of a major
disaster for the State of Texas (FEMA–
4485–DR), dated March 25, 2020, and
related determinations.
SUMMARY:
VerDate Sep<11>2014
18:26 Apr 13, 2020
Jkt 250001
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
The declaration was issued
March 25, 2020.
DATES:
FOR FURTHER INFORMATION CONTACT:
Dean Webster, Office of Response and
Recovery, Federal Emergency
Management Agency, 500 C Street SW,
Washington, DC 20472, (202) 646–2833.
Notice is
hereby given that, in a letter dated
March 25, 2020, the President issued a
major disaster declaration under the
authority of the Robert T. Stafford
Disaster Relief and Emergency
Assistance Act, 42 U.S.C. 5121 et seq.
(the ‘‘Stafford Act’’), as follows:
SUPPLEMENTARY INFORMATION:
I have determined that the emergency
conditions in the State of Texas resulting
from the Coronavirus Disease 2019 (COVID–
19) pandemic beginning on January 20, 2020,
E:\FR\FM\14APN1.SGM
14APN1
]]>Agencies
[Federal Register Volume 85, Number 72 (Tuesday, April 14, 2020)]
[Notices]
[Pages 20698-20699]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-07708]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day Comment Request; Early Career
Reviewer Program Online Application and Vetting System (Center for
Scientific Review)
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In compliance with the Paperwork Reduction Act of 1995, the
National Institutes of Health (NIH) has submitted to the Office of
Management and Budget (OMB) a request for review and approval of the
information collection listed below.
DATES: Comments regarding this information collection are best assured
of having their full effect if received within 30-days of the date of
this publication.
ADDRESSES: Written comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular
[[Page 20699]]
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the data collection plans and
instruments, contact: Dr. Hope Cummings, Project Clearance Liaison,
Center for Scientific Review, NIH, Room 4134, 6701 Rockledge Drive,
Bethesda, Maryland, 20892 or call non-toll-free number (301) 402-4706
or Email your request, including your address to:
[email protected]. Formal requests for additional plans and
instruments must be requested in writing.
SUPPLEMENTARY INFORMATION: This proposed information collection was
previously published in the Federal Register on January 31, 2020, pages
5677-5678 (85 FR 21) and allowed 60 days for public comment. No public
comments were received. The purpose of this notice is to allow an
additional 30 days for public comment. The Center for Scientific Review
(CSR), National Institutes of Health, may not conduct or sponsor, and
the respondent is not required to respond to, an information collection
that has been extended, revised, or implemented on or after October 1,
1995, unless it displays a currently valid OMB control number.
In compliance with Section 3507(a)(1)(D) of the Paperwork Reduction
Act of 1995, the National Institutes of Health (NIH) has submitted to
the Office of Management and Budget (OMB) a request for review and
approval of the information collection listed below.
Proposed Collection: Early Career Reviewer Program Online
Application and Vetting System--0925-0695, REVISION--expiration date
05/31/2020, Center for Scientific Review (CSR), National Institutes of
Health (NIH).
Need and Use of Information Collection: The Center for Scientific
Review (CSR) is the portal for NIH grant applications and their review
for scientific merit. Our mission is to see that all NIH grant
applications receive fair, independent, expert, and timely reviews--
free from inappropriate influences--so NIH can fund the most promising
research. To accomplish this goal, Scientific Review Officers (SRO)
form study sections consisting of scientists who have the technical and
scientific expertise to evaluate the merit of grant applications. Study
section members are generally scientists who have established
independent programs of research as demonstrated by their publications
and their grant award experiences.
The CSR Early Career Reviewer program was developed to identify and
train qualified scientists who are early in their scientific careers
and who have not had prior CSR review experience. The goals of the
program are to expose these early career scientists to the peer review
experience so that they become more competitive as applicants as well
as to enrich the existing pool of NIH reviewers. Currently, the online
application software, the Early Career Reviewer Application and Vetting
System, is accessed online by applicants to the Early Career Reviewer
Program who provide information such as their name, contact
information, a description of their areas of expertise, their study
section preferences, and their professional Curriculum Vitae. This
Information Collection Request (ICR) is to revise the Early Career
Reviewer Application and Vetting System to include additional questions
and be more user friendly. Additional questions are in line with NIH's
renewed Interest in Diversity (NOT-OD-20-031) and include questions
such as applicants' race, ethnicity, gender, disability, and
disadvantage backgrounds. Applicants can choose if they would like to
answer these additional questions (i.e. optional). Applicants are also
now able to check their eligibility before applying to the program.
OMB approval is requested for 3 years. There are no costs to
respondents other than their time. The total estimated annualized
burden hours are 505.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average time
Type of respondent Number of responses per per response Total annual
respondents respondent (in hours) burden hour
----------------------------------------------------------------------------------------------------------------
Research scientists............................. 1212 1 25/60 505
---------------------------------------------------------------
Total....................................... .............. 1212 .............. 505
----------------------------------------------------------------------------------------------------------------
Dated: March 30, 2020.
Hope M. Cummings,
Project Clearance Liaison, Center for Scientific Review (CSR), National
Institutes of Health.
[FR Doc. 2020-07708 Filed 4-13-20; 8:45 am]
BILLING CODE 4140-01-P
